Elanco

Respiratory Solutions

SWINE RESPIRATORY DISEASE


Having a strong health protocol involves planning ahead and being prepared for challenges. Swine respiratory disease (SRD) is the number one cause of nursery death¹ and is endemic in many herds worldwide.² There is no one-size-fits-all treatment option. It is a combination of many considerations: the prevalence of the pathogen, an evaluation of its susceptibility and herd-specific goals. With a well-thought-out strategy, you can stop the spread or even get completely ahead before SRD starts expressing clinically.

Getting ahead of a challenge and making sure you're choosing the right treatment solution is critical. Use every resource at your disposal to get the Full Value out of every pig. Elanco offers vaccine, injectable, feed, and water-soluble solutions for industry-critical respiratory challenges.

PRODUCTS		Elanco Pradalex (swideflauech hytecline)	Baytril 100 (enrofloxacin)	Elanco Interexxa: 25 dutativanyoti Njeckup	Elanco Increxxa Automagyita Ajectica	Elanco Tytan Injection
KEY MESSAGES		Quick. Dual action. Convenient.	Quick. Reliable. Effective.	Proven. Rapid.* Backed.	Proven. Rapid.* Backed.	Effective. Multi-disease. Control.
ACTIVE INGREDIENT		pradofloxacin	enrofloxacin	tulathromycin	tulathromycin	tylosin
PATHOGEN	INDICATION					
Actinobacillus pleuropneumoniae (APP)	Control		ē	ä	ä	
	Treat		Å	ä	Å	
Pasteurella multocida	Control		å	<u> </u>	å	
	Treat	Å	Ê	<u> </u>	Å	Å
Glaesserella parasuis	Control		Ê			
(Haemophilus parasuis)	Treat	Å	Ĝ	<u> </u>	Å	
	Control		å			
Streptococcus suis	Treat	Å	Ĝ			
	Control		Ê			
Bordetella bronchiseptica	Treat	ä	<u> </u>	<u> </u>	<u> </u>	
Mycoplasma	Control		Ĝ	<u> </u>	Å	
hyopneumoniae (M. hyo)	Treat	Å	Å	<u> </u>	Å	
Porcine reproductive and respiratory syndrome virus (PRRSv)	Control					
	Treat					
Immune Support						
DOSAGE		1.7 mL / 100 lbs	3.4 mL / 100 lbs	1 mL / 22 lbs	1 mL / 88 lbs	1 mL / 12.5 lbs (50 mg) 1 mL / 25 lbs (100 mg)
MEAT WITHDRAWAL (days)		2	5	5	5	14

Elanco Pulmotil'AC titricosis phosphote Elanco Pulmotil. Elanco Prevacent. Safe. Smooth. Quick. Effective. Quick. Flexible. Easy. Effective. Effective. tilmicosin tilmicosin MLV phosphate 回 回 \Diamond \triangle \triangle AL. 1 mL 200 mg / liter 181-363 g / ton intramuscularly 7 7 21

*Clinical relevance unknown **Only for Mycoplasma hyopneumoniae in the presence of PRRS.



ECONOMIC IMPLICATIONS OF SRD

Diseases are costly on their own - but what about when you compound multiple challenges? The additive cost of pathogen combinations can grow rapidly. This economic impact is calculated based on a number of factors, including an increase in mortality, culls and tailenders (MCT) and a reduction in average daily gain (ADG). The impact of multiple challenges is also exponential combined challenges can double or triple the economic impact on your bottom line.³

ADDITIVE CO	ST OF	PATHO	GENS ¹
-------------	-------	-------	--------------------------

M. hyo	\$0.63
PRRS	\$5.57
SIV	\$3.23
PRRS and <i>M. hyo</i>	\$9.69
PRRS and SIV	\$10.41
SIV and <i>M. hyo</i>	\$10.12

BARRICADE	Elonco Swine Awake	Elanco Denagard. LC	Elanco Denagard. +crc
Complement. Customize. Protect.	Awaken. Support. Improve.	Dependable. Effective. Treatment.	
killed autogenous	dried Bacillus licheniformis, dried Lactobacillus casei fermentation product and citric acid	tiamulin hydrogen fumarate	
		•	
		0	
₽¥			
	\Diamond		
1 - 2 mL intranasally	1 pk / day / 1,200 pigs	1 L / day / 1,786 pigs	35 g / ton
21		3	2

ADDITIVE PRODUCTION IMPACTS OF PATHOGENS¹

	Difference from baseline in %MCT	Difference from baseline in ADG
M. hyo	2.15%	0.04
PRRS	1.68%	-0.11
SIV	1.87%	-0.04
PRRS and M. hyo	5.43% **M**P	-0.04*M*P
PRRS and SIV	4.34% **S**P	-0.1**S
SIV and <i>M. hyo</i>	3.46% **M*S	-0.18**S

*M,P,S = combinations vs. M/P/S; P < 0.1 **M,P,S = combinations vs. M/P/S; P < 0.05

Contact your Elanco representative to find the right solutions for your operation. Learn more at farmanimal.elanco.com/us/swine.

The labels contain complete use information, including cautions and warnings. Always read, understand and follow the labels and use directions.

- For the control of swine respiratory disease associated with Pasteurella multocida and Haemophilus parasuis. For the control of swine respiratory disease associated with
- Mycoplasma hyopneumoniae in the presence of porcine reproductive and respiratory syndrome virus (PRRSv) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

- Must be diluted before administration to animals. Include in the drinking water to provide a concentration of 200 mg tilmicosin per liter (200 ppm).
- One 960 mL bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs.
- The medicated water should be administered for (5) five consecutive days.
- Use within 24 hours of mixing with water. Do not use rusty containers for medicated water as they may
- affect product integrity. When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 mL) of Pulmotil AC per 2.5 gallons of stock solution.

Before using this product, it is important to read the entire product insert, including the boxed human warning.

WARNING: Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin. Avoid direct skin and eye contact. In case of human exposure, call 1-800-722-0987 and consult a physician immediately.

Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water

CAUTION: Federal law restricts this drug to use by or on the

- order of a licensed veterinarian. For use only in swine. Not for injection. Injection of tilmicosin has been shown to be fatal in swine and non-human
- primates, and may be fatal in horses and goats. Swine intended for human consumption must not be slaughtered within 7 days of treatment.
- Always treat the fewest number of animals necessary to control a respiratory disease outbreak. Prescriptions shall not be refilled.
- Concurrent use of Pulmotil AC and another macrolide by any route, or use of another macrolide immediately following this use of Pulmotil AC is not advised.
- Ensure that pigs have continuous access to medicated water during the treatment period. Monitor pigs for signs of water refusal and dehydration while being treated.



Scan me for the complete label

- For the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis. Bordetella bronchiseptica. Mycoplasma
- hyopneumoniae. For the control of colibacillosis in groups or pens of weaned
- pigs where colibacillosis associated with Escherichia coli has been diagnosed.
- Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site.
- For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are present in at least 2% of the animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law prohibits the extra-label use of this drug in food-producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.

- Not for use in humans. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately
- flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water Consult a physician if irritation persists following ocular or

dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to guinolones. If excessive accidental exposure occurs, avoid direct sunlight.

- Increxxa Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
- Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

ATION CAUTION: Federal (USA) law restricts this drug to use by or on

- the order of a licensed veterinarian.
 WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.
- Swine intended for human consumption must not be slaughtered within 5 days from the last treatment. The effects of Increxxa on porcine reproductive performance,
- pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue
- reaction that may result in trim loss of edible tissue at slaughter.
- Store below 25°C (77°F), with excursions up to 40°C (104°F). 100 mL: Use within 2 months of first puncture and puncture a maximum of 67 times. If more than 67 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.

- · 250 mL and 500 mL: Use within 2 months of first puncture and puncture a maximum of 100 times. If more than 100 punctures are anticipated, the use of
- multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.

PRADALEX INDICATIONS

Pradalex is indicated for the treatment of SRD associated with Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis. Pasteurella multocida. Streptococcus suis and Mycoplasma hyopneumoniae in weaned swine intended for slaughter (nursery, growing, and finishing swine boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter). Not for use in swine intended for breeding (boars intended for breeding, replacement gilts and sows intended for breeding) and in nursing piglets.

D ADMINISTRATION

Swine: Administer once as an intramuscular injection in the neck at a dosage of 7.5 mg/kg (1.7 mL/100 lb) body weight. Do not inject more than 5 mL per intramuscular injection site

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in humans. Keep out of reach of children. Avoid contact with eyes and skin. Individuals with a history of hypersensitivity to quinolones should avoid this product. Not for use in animals intended for breeding because the effects of Pradalex on swine reproductive performance, pregnancy and lactation have not been determined. Not for use in nursing piglets because safety and effectiveness have not been demonstrated. Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. Mild to moderate inflammatory changes of the injection site may be seen in swine treated with Pradalex. See package insert for additional safety information.

- For the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp.; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by the appropriate medication in the drinking water and/or feed.
- Inject intramuscularly 4 mg per pound of body weight (1 mL per 50 lbs) twice daily. Treatment should be continued 24 hours following remission of disease signs, not to exceed 3 days. Do not inject more than 5 mL per site

CAUTION: Federal law restricts this drug to use by or on the

- order of a licensed veterinarian. WARNING: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN.
- Adverse reactions, including shock and death may result from overdosage in baby pigs. Do not attempt injection into pigs weighing less than 25 lbs (0.5 mL) with the common syringe. It is recommended that Tylan 50
- Injection be used in pigs weighing less than 25 lbs. Do not administer to horses or other equines. Injection of tylosin in equines has been fatal.
- Swine intended for human consumption must not be slaughtered within 14 days of the last use of this drug product.
- If tylosin medicated drinking water is used as a follow-up treatment for swine dysentery, the animal should thereafter receive feed containing 40 to 100 grams of tylosin per ton for 2 weeks to assure depletion of tissue residues.

1USDA APHIS Veterinary Services. "Swine 2006, Part 1: References of Swine Health and Management Practices in the United States, 2006." 2007.

³Merck & Co. "Respiratory Disease of Pigs: Introduction." The Merck Veterinary Manual. Available at: www.merckvetmanual.com/wmn/htm/bc/1400/htm. Accessed March 31, 2009. ³Haden CD, Painter T, Fangman T, Holtkamp D. Assessing production parameters and economic impact of swine influenza , PRRS and *Mycoplasma hyopneumoniae* on finishing pigs in a large production system. American Association of Swine Veterinarians. 2012 April: 75-76.

Denagard, Increxxa, Pradalex, Prevacent, Pulmotil, Swine Awake, Tylan, the Full Value Pork logo, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Baytril is sold by Elanco or its affiliates and is not a product of Bayer. Baytril is owned by Bayer and used under license. Barricade is a trademark of Aptimmune Biologics, Inc.



